US20050069505A1 - Orally administrable composition for the photoprotection of the skin - Google Patents

Orally administrable composition for the photoprotection of the skin Download PDF

Info

Publication number
US20050069505A1
US20050069505A1 US10/505,305 US50530504A US2005069505A1 US 20050069505 A1 US20050069505 A1 US 20050069505A1 US 50530504 A US50530504 A US 50530504A US 2005069505 A1 US2005069505 A1 US 2005069505A1
Authority
US
United States
Prior art keywords
bifidobacterium
group
lactic acid
cncm
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/505,305
Inventor
Lionel Breton
Isabelle Bureau-Franz
Chantal Fanchon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Assigned to NESTEC S.A. reassignment NESTEC S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRETON, LIONEL, BUREAU-FRANZ, ISABELLE, FANCHON, CHANTAL
Publication of US20050069505A1 publication Critical patent/US20050069505A1/en
Priority to US11/772,704 priority Critical patent/US10688139B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria

Definitions

  • the present invention relates to orally administrable composition or pharmaceutical compositions, or cosmetical compositions, for the protection of the skin against negative effects from the environment, in particular exposure to solar radiation, which is orally administrable, and a method to improve the photoprotection of the skin.
  • the present invention aims to provide an orally administrable composition for the photoprotection of the skin which comprises a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, included into an orally acceptable carrier.
  • the present invention further relates to the use of a photoprotecting effective amount of at least one probiotic lactic acid bacterium or a culture supernatant thereof and at least one carotenoid, included into an orally acceptable carrier for preparing an orally administrable composition for protecting the skin against solar radiations such as ultraviolet and all related skin disorders, such as erythema, inflammation, sun burn, barrier function, photoageing, alteration of the immune system, for example.
  • solar radiations such as ultraviolet and all related skin disorders, such as erythema, inflammation, sun burn, barrier function, photoageing, alteration of the immune system, for example.
  • the invention relates to a method for improving the photoprotective function of the skin, which comprises the step of orally administering to the individual a composition comprising a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, in an orally acceptable carrier.
  • the combination according to the present invention has a particular beneficial effect on skin protection and coloration of the skin that helps to reduce the effects of solar radiation-related stress on skin.
  • NCC designates Nestle Culture Collection (Nestlé Research Center, Vers-chez-les-Blanc, Lausanne, Switzerland).
  • photoprotection is used to describe attempt to block or reduce the adverse clinical, histological and immunological effects of solar radiation exposure on the skin.
  • the subject compositions comprise, as the active agents therefor, combinatory immixture of at least one probiotic lactic acid bacterium or a culture supernatant thereof, and at least one carotenoid or derivative.
  • Probiotics are non-pathogenic and non-toxigenic organisms that survive passage through the stomach and small intestine. Upon continuous ingestion by the host they eventually may colonize the gut to a substantial extent thus competing with other potentially pathogenic bacteria for nutrients and/or attachment sites on the gastro-intestinal wall and reducing their numbers and reducing or preventing infections. Until now a number of different probiotic microorganisms have been found, which all are reported to exert their effect in the gut via the production of toxins, metabolic by-products, short chain fatty acids and the like.
  • composition having a synergistic photoprotective effect on the skin may be obtained by combining into an orally acceptable carrier, a probiotic microorganism and an active compound such as carotenoid.
  • the probiotic to be included into the carrier is selected from the group consisting of lactic acid bacteria, in particular Lactobacilli and/or Bifidobacteria and are more preferably Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei or Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum , or a mixture thereof.
  • Lactobacilli and/or Bifidobacteria are more preferably Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacill
  • the strains Lactobacillus johnsonii NCC 533 , Lactobacillus paracasei NCC 2461 , Bifidobacterium adolescentis NCC 251 and Bifidobacterium longum NCC 490 were deposited by way of an example, under the Budapest Treaty with the Institut Pasteur (28 rue du Dondel Roux, F-75024 Paris cédex 15) on 30.06.92, 12.01.99, 15.04.99 and 15.03.99, respectively and under the deposit number CNCM I-1225, CNCM I-2116, CNCM I-2168 and CNCM I-2170, respectively.
  • the strain of Bifidobacterium lactis (ATCC27536) provided by Hansen (Chr. Hansen A/S, 10-12 Boege Alle, P.O. Box 407, DK-2970 Hoersholm, Danemark) can also be used.
  • the probiotic microorganism according to the present invention may be included in a live form, dead form, semi-active or in deactivated form and fragments or fractions originating from the microorganism either live or dead e.g. as a lyophilized powder.
  • culture supernatants of the microorganisms may be included in the products, optionally in concentrated form. It may also be included in an encapsulated form.
  • the supernatant may be used as such or may be subjected to one or more purification steps prior to inclusion into the product, so as to concentrate or isolate the active ingredient (s)/metabolite (s).
  • Method and techniques for purifying compounds and detecting the activity thereof in the fractions obtained are well known to the skilled person.
  • the probiotic lactic acid bacteria may be present in the carrier in an amount of at least 10 5 cfu/g of carrier and preferably from about 10 5 to 10 15 cfu/g of orally acceptable carrier, and more preferably from 10 7 to 10 12 cfu/g of orally acceptable carrier.
  • the carotenoid may be a carotenoid with or without provitamin A activity. It may be ⁇ -carotene, ⁇ -carotene, ⁇ -carotene, lycopene, zeaxanthine and luteine, or a mixture thereof.
  • the carotenoid may be from synthetic or natural origin or contained in a natural extract. When the carotenoid is from natural origin, it is preferably obtained from plant material, in which the plant is grown in-vivo or in-vitro. Method for extracting the carotenoids is well known in the art.
  • the carotenoid may be present in the carrier in an amount of from 10-12% to 20% by weight and preferably from 0.00001 mg to 50 mg/day and more preferably from 0.001 mg to 30 mg/day.
  • a mixture of a plurality of lactic acid bacteria or carotenoids may also be used.
  • the carrier may be any food or pharmaceutical product, or a nutritional supplement for oral administration or a composition for oral administration, wherein the probiotic microorganism and the carotenoid may be included.
  • food or pharmaceuticals carriers are milk, yoghurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk based powders, infant formulae or tablets, liquid suspensions, dried oral supplement, wet oral supplement, dry-tube-feeding.
  • the nutritionally supplement for oral administration may be in capsules, soft capsules, tablets, pastes or pastilles, gums, or drinkable solutions or emulsions. Methods for preparing the carrier are common knowledge.
  • the composition according to the invention may further comprise bioactive molecules or yeast extracts, for example.
  • the yeast is any food-grade yeast selected from the group consisting of Ascomycotina or Deuteromycotina.
  • the yeast may be selected from the group consisting of Debaryomyces, Kluyveromyces, Saccharomyces, Yarrowia, Zygosaccharomyces, Candida and Rhodutorula , and more preferably Saccharomyces caerevisae (baker's yeast).
  • Such yeast may be used in the form of dried or lyophilized extracts. It may be present in the carrier in an amount of at least 10 5 cfu/g of orally acceptable carrier, preferably from about 10 5 to 10 15 cfu/g of orally acceptable carrier, and more preferably from 10 7 to 10 12 cfu/g of orally acceptable carrier, said amount depending on the nature and activity of the particular yeast.
  • composition according to the invention may also comprise usual excipients, in particular sweeteners, flavouring agents or preservatives.
  • composition according to the invention provides a surprising and synergistic protective and preventive effect of the skin.
  • the invention relates to a method for improving the photoprotective function of the skin, which comprises the step of orally administering to an individual a composition comprising a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, in an orally acceptable carrier.
  • the amount of the composition to be consumed by the individual will depend on the desirable effect. However, an amount of the composition to provide a daily amount of about 10 5 to 10 15 organisms, which organism may be alive or dead, and from 0.00001 mg to 50 mg of carotenoids, would usually are adequate.
  • composition is administered to an individual before or during the exposure to ultraviolet radiation, in particular exposure to sun.
  • ultraviolet radiation in particular exposure to sun.
  • ⁇ -carotene is provided by Roche
  • Lycopene is provided by Lycored
  • Lyophilized S. cerevissae is provided by BioSpringer
  • Latobacillus CNCM I-1225 dry mix Lactobacillus CNCM I-2116 or Bifidobacterium CNCM I-2168 dry mix are prepared so that they contain 1.10 8 to 1.10 9 organisms.
  • a photoprotective daily orally administrable composition is prepared as follows: ⁇ -carotene 4.7 mg Latobacillus CNCM I-1225 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • composition is administered to the individual in an amount of 2 ⁇ 500 mg daily, which provides a protective and preventive effect of the skin.
  • a photoprotective daily orally administrable composition is prepared as follows: ⁇ -carotene 4.7 mg Zeaxanthine 10 mg Latobacillus CNCM I-1225 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • composition is administered to the individual in an amount of 2 ⁇ 500 mg daily, which provides a protective and preventive effect of the skin.
  • a photoprotective daily orally administrable composition is prepared as follows: ⁇ -carotene 4.7 mg Lycopene 2.5 mg Bifidobacterium CNCM I-2168 dry mix 30 mg Latobacillus CNCM I-1225 dry mix 30 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • composition is administered to the individual in an amount of 2 ⁇ 500 mg daily, which provides a protective and preventive effect of the skin.
  • a photoprotective daily orally administrable composition is prepared as follows: Lycopene 2.5 mg Lyophilized S. cerevissae 75 mg Latobacillus CNCM I-2116 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • composition is administered to the individual in an amount of 2 ⁇ 500 mg daily, which provides a protective and preventive effect of the skin.
  • a photoprotective daily orally administrable composition is prepared as follows: ⁇ -carotene 4.7 mg Lycopene 2.5 mg Lyophilized S. cerevissae 75 mg Latobacillus CNCM I-1225 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • a photoprotective daily orally administrable composition is prepared as follows: ⁇ -carotene 4.7 mg Lyophilized S. cerevissae 75 mg Latobacillus CNCM I-1225 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • composition is administered to the individual in an amount of 2 ⁇ 500 mg daily, which provides a protective and preventive effect of the skin.

Abstract

An orally administrable composition for the photoprotection of the skin which comprises the combination of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, included into an orally acceptable carrier.

Description

    FIELD OF THE INVENTION
  • The present invention relates to orally administrable composition or pharmaceutical compositions, or cosmetical compositions, for the protection of the skin against negative effects from the environment, in particular exposure to solar radiation, which is orally administrable, and a method to improve the photoprotection of the skin.
    • BACKGROUND OF THE INVENTION
  • The continuous decrease of the atmosphere's ozone layer with the concurrent increase of ultraviolet radiation reaching the planet's surface has attracted a great deal of interest in its potential consequence on human health. Although exposure to ultraviolet radiation is needed for humans to produce vitamin D, growing evidence suggests that extensive exposure to sun-light, in particular to ultraviolet radiation, causes a variety of problems in the skin, including induction of certain skin cancers and induction of accelerated skin ageing.
  • In addition to these established health concerns, research has also provided evidence suggesting that exposure to ultraviolet radiation may negatively affect a variety of immune responses in living beings both locally, within the UV-irradiated skin, and also systemically, i.e. at sites distant from the irradiated skin.
  • It is thus important to alleviate the detrimental effects of ultraviolet radiation on the skin, and also prevent the development of erythema, oedema and/or flaking or scaling (hyperkeratosis) of the skin.
  • In the art, there have been several attempts, such as by using sunscreens or other particular pharmacological agents.
  • In J. Invest. Dermatol., 97 (1991), 624-628 it is reported that topical application of ultraviolet radiation-absorbing compounds (sunscreens) is effective in preventing ultraviolet radiation-induced erythema and edema but cannot prevent UV-light induced immuno-suppression. This finding was confirmed by several other studies, according to which sunscreens seems to prevent inflammation or irritation but do not provide complete prophylactic protection against the immuno-suppressive effects of ultraviolet radiation.
  • On the other hand, In FR 2698 268 (L'Oreal) an orally administrable composition comprising a combination of at least one amino-acid, salt of copper and a mix of vitamins has been shown to protect the skin against ultraviolet radiation.
  • However, there is still a need in the art for an orally administrable composition, which is capable to improve and/or reinforce the photoprotective function of the skin.
    • SUMMARY OF THE INVENTION
  • Accordingly, in a first aspect the present invention aims to provide an orally administrable composition for the photoprotection of the skin which comprises a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, included into an orally acceptable carrier.
  • The present invention further relates to the use of a photoprotecting effective amount of at least one probiotic lactic acid bacterium or a culture supernatant thereof and at least one carotenoid, included into an orally acceptable carrier for preparing an orally administrable composition for protecting the skin against solar radiations such as ultraviolet and all related skin disorders, such as erythema, inflammation, sun burn, barrier function, photoageing, alteration of the immune system, for example.
  • In a last aspect, the invention relates to a method for improving the photoprotective function of the skin, which comprises the step of orally administering to the individual a composition comprising a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, in an orally acceptable carrier.
  • The combination according to the present invention has a particular beneficial effect on skin protection and coloration of the skin that helps to reduce the effects of solar radiation-related stress on skin.
  • Additional features and advantages of the present invention are described in, and will be apparent from, the following Detailed Description of the Invention.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Within the following description, “NCC” designates Nestle Culture Collection (Nestlé Research Center, Vers-chez-les-Blanc, Lausanne, Switzerland). The term “photoprotection” is used to describe attempt to block or reduce the adverse clinical, histological and immunological effects of solar radiation exposure on the skin.
  • According to the present invention, the subject compositions comprise, as the active agents therefor, combinatory immixture of at least one probiotic lactic acid bacterium or a culture supernatant thereof, and at least one carotenoid or derivative.
  • Indeed, it has now surprisingly and unexpectedly been determined that admixture of these two very specific constituents elicits an enhanced effect or response in respect of the photoprotection of the skin.
  • Probiotics are non-pathogenic and non-toxigenic organisms that survive passage through the stomach and small intestine. Upon continuous ingestion by the host they eventually may colonize the gut to a substantial extent thus competing with other potentially pathogenic bacteria for nutrients and/or attachment sites on the gastro-intestinal wall and reducing their numbers and reducing or preventing infections. Until now a number of different probiotic microorganisms have been found, which all are reported to exert their effect in the gut via the production of toxins, metabolic by-products, short chain fatty acids and the like.
  • It has now been shown that probiotics do also exert an effect in an individual's body at a location distant from the region in which they colonize it. And particularly, it has been surprisingly found that a composition having a synergistic photoprotective effect on the skin may be obtained by combining into an orally acceptable carrier, a probiotic microorganism and an active compound such as carotenoid.
  • In a preferred embodiment, the probiotic to be included into the carrier is selected from the group consisting of lactic acid bacteria, in particular Lactobacilli and/or Bifidobacteria and are more preferably Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei or Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, or a mixture thereof.
  • According to a most preferred embodiment the strains Lactobacillus johnsonii NCC 533, Lactobacillus paracasei NCC 2461, Bifidobacterium adolescentis NCC 251 and Bifidobacterium longum NCC 490 were deposited by way of an example, under the Budapest Treaty with the Institut Pasteur (28 rue du Docteur Roux, F-75024 Paris cédex 15) on 30.06.92, 12.01.99, 15.04.99 and 15.03.99, respectively and under the deposit number CNCM I-1225, CNCM I-2116, CNCM I-2168 and CNCM I-2170, respectively.
  • The strain of Bifidobacterium lactis (ATCC27536) provided by Hansen (Chr. Hansen A/S, 10-12 Boege Alle, P.O. Box 407, DK-2970 Hoersholm, Danemark) can also be used.
  • The probiotic microorganism according to the present invention may be included in a live form, dead form, semi-active or in deactivated form and fragments or fractions originating from the microorganism either live or dead e.g. as a lyophilized powder. Also culture supernatants of the microorganisms may be included in the products, optionally in concentrated form. It may also be included in an encapsulated form. When using a supernatant of a probiotic's culture the supernatant may be used as such or may be subjected to one or more purification steps prior to inclusion into the product, so as to concentrate or isolate the active ingredient (s)/metabolite (s). Method and techniques for purifying compounds and detecting the activity thereof in the fractions obtained are well known to the skilled person.
  • The probiotic lactic acid bacteria may be present in the carrier in an amount of at least 105 cfu/g of carrier and preferably from about 105 to 1015 cfu/g of orally acceptable carrier, and more preferably from 107 to 1012 cfu/g of orally acceptable carrier.
  • The carotenoid may be a carotenoid with or without provitamin A activity. It may be β-carotene, γ-carotene, α-carotene, lycopene, zeaxanthine and luteine, or a mixture thereof. The carotenoid may be from synthetic or natural origin or contained in a natural extract. When the carotenoid is from natural origin, it is preferably obtained from plant material, in which the plant is grown in-vivo or in-vitro. Method for extracting the carotenoids is well known in the art. The carotenoid may be present in the carrier in an amount of from 10-12% to 20% by weight and preferably from 0.00001 mg to 50 mg/day and more preferably from 0.001 mg to 30 mg/day.
  • A mixture of a plurality of lactic acid bacteria or carotenoids may also be used.
  • The carrier may be any food or pharmaceutical product, or a nutritional supplement for oral administration or a composition for oral administration, wherein the probiotic microorganism and the carotenoid may be included. Examples for food or pharmaceuticals carriers are milk, yoghurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk based powders, infant formulae or tablets, liquid suspensions, dried oral supplement, wet oral supplement, dry-tube-feeding. The nutritionally supplement for oral administration may be in capsules, soft capsules, tablets, pastes or pastilles, gums, or drinkable solutions or emulsions. Methods for preparing the carrier are common knowledge.
  • The composition according to the invention may further comprise bioactive molecules or yeast extracts, for example. In a preferred embodiment, the yeast is any food-grade yeast selected from the group consisting of Ascomycotina or Deuteromycotina. In a preferred embodiment, the yeast may be selected from the group consisting of Debaryomyces, Kluyveromyces, Saccharomyces, Yarrowia, Zygosaccharomyces, Candida and Rhodutorula, and more preferably Saccharomyces caerevisae (baker's yeast).
  • Such yeast may be used in the form of dried or lyophilized extracts. It may be present in the carrier in an amount of at least 105 cfu/g of orally acceptable carrier, preferably from about 105 to 1015 cfu/g of orally acceptable carrier, and more preferably from 107 to 1012 cfu/g of orally acceptable carrier, said amount depending on the nature and activity of the particular yeast.
  • The composition according to the invention may also comprise usual excipients, in particular sweeteners, flavouring agents or preservatives.
  • The composition according to the invention provides a surprising and synergistic protective and preventive effect of the skin.
  • Accordingly, in another aspect, the invention relates to a method for improving the photoprotective function of the skin, which comprises the step of orally administering to an individual a composition comprising a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, in an orally acceptable carrier.
  • The amount of the composition to be consumed by the individual will depend on the desirable effect. However, an amount of the composition to provide a daily amount of about 105 to 1015 organisms, which organism may be alive or dead, and from 0.00001 mg to 50 mg of carotenoids, would usually are adequate.
  • The composition is administered to an individual before or during the exposure to ultraviolet radiation, in particular exposure to sun. When the exposure period is foreseeable, it is desirable to start the consumption before the exposure and preferably 1 to 2 months before, and to prolong consumption during exposure.
  • The following examples are given by way of illustration only and in no way should be construed as limiting the subject matter of the present application. All percentages are given by weight unless otherwise indicated.
    • EXAMPLES
  • In the following examples 1 to 6, β-carotene is provided by Roche, Lycopene is provided by Lycored, Lyophilized S. cerevissae is provided by BioSpringer, Latobacillus CNCM I-1225 dry mix, Lactobacillus CNCM I-2116 or Bifidobacterium CNCM I-2168 dry mix are prepared so that they contain 1.108 to 1.109 organisms.
    • Example 1
  • A photoprotective daily orally administrable composition is prepared as follows:
    β-carotene 4.7 mg
    Latobacillus CNCM I-1225 dry mix 50 mg
    Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • The composition is administered to the individual in an amount of 2×500 mg daily, which provides a protective and preventive effect of the skin.
    • Example 2
  • A photoprotective daily orally administrable composition is prepared as follows:
    β-carotene 4.7 mg
    Zeaxanthine 10 mg
    Latobacillus CNCM I-1225 dry mix 50 mg
    Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • The composition is administered to the individual in an amount of 2×500 mg daily, which provides a protective and preventive effect of the skin.
    • Example 3
  • A photoprotective daily orally administrable composition is prepared as follows:
    β-carotene 4.7 mg
    Lycopene 2.5 mg
    Bifidobacterium CNCM I-2168 dry mix 30 mg
    Latobacillus CNCM I-1225 dry mix 30 mg
    Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • The composition is administered to the individual in an amount of 2×500 mg daily, which provides a protective and preventive effect of the skin.
    • Example 4
  • A photoprotective daily orally administrable composition is prepared as follows:
    Lycopene 2.5 mg
    Lyophilized S. cerevissae 75 mg
    Latobacillus CNCM I-2116 dry mix 50 mg
    Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • The composition is administered to the individual in an amount of 2×500 mg daily, which provides a protective and preventive effect of the skin.
    • Example 5
  • A photoprotective daily orally administrable composition is prepared as follows:
    β-carotene 4.7 mg
    Lycopene 2.5 mg
    Lyophilized S. cerevissae 75 mg
    Latobacillus CNCM I-1225 dry mix 50 mg
    Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • The composition is administered to the individual in an amount of 2×500 mg daily, which provides a protective and preventive effect of the skin.
    • Example 6
  • A photoprotective daily orally administrable composition is prepared as follows:
    β-carotene 4.7 mg
    Lyophilized S. cerevissae 75 mg
    Latobacillus CNCM I-1225 dry mix 50 mg
    Glucidex IT 19 (maltodextrin powder) QSP 500 mg
  • The composition is administered to the individual in an amount of 2×500 mg daily, which provides a protective and preventive effect of the skin.
  • It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.

Claims (30)

1. An orally administrable composition for the photoprotection of the skin comprising a photoprotecting effective amount of at least one probiotic lactic acid bacterium or a culture supernatant thereof, and at least one carotenoid or derivative, included in an orally acceptable carrier.
2. A composition according to claim 1, wherein the lactic acid bacterium is selected from the group consisting of Lactobacilli and Bifidobacteria.
3. A composition according to claim 1, wherein the lactic acid bacterium is selected from the group consisting of Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei or Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, and mixtures thereof.
4. A composition according to claim 1, wherein the lactic acid bacterium is selected from the group consisting of CNCM I-1225, CNCM I-2116, CNCM I-2168 and CNCM I-2170.
5. A composition according to claim 1, wherein the probiotic lactic acid bacterium is included in the carrier in a form selected from the group consisting of live form, semi-active and deactivated form.
6. A composition according to claim 1, wherein the carotenoid is selected from the group consisting of a cartenoid with and without provitamin A activity.
7. A composition according to claim 1, wherein the carrier is a food.
8. A composition according to claim 7, wherein the food is selected from the group consisting of milk, yoghurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk based powders, and infant formula.
9. A composition according to claim 8, wherein the food may be in a drinkable solution.
10. A composition according to claim 1, which further comprises a component selected from the group consisting of a yeast extract and a bioactive molecule.
11. A method for producing an orally administrable composition for the protection of the skin comprising the steps of using a photoprotecting effective amount of at least one probiotic lactic acid bacterium or a culture supernatant thereof and at least one carotenoid, included in an orally acceptable carrier, for preparing the composition.
12. The method according to claim 11, wherein the lactic acid bacterium is selected from the group consisting of Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei or Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, and mixtures thereof.
13. The method according to claim 11, wherein the lactic acid bacterium is selected from the group consisting of CNCM I-1225, CNCM I-2116, CNCM I-2168, CNCM I-2170 and ATCC 27536.
14. The method according to claim 11, wherein the probiotic lactic acid bacterium is present in the carrier in an amount of from about 105 to 1012 cfu/g of the carrier.
15. The method according to claim 11, wherein the carotenoid is present in the carrier in an amount of from 10% to 20% by weight.
16. A method for improving the photoprotective function of the skin, which comprises the step of orally administering to an individual a therapeutically-effective amount of a composition comprising the combination of at least one probiotic lactic acid bacteria or a culture supernatant thereof, and at least one carotenoid or derivative, in an orally acceptable carrier.
17. A method according to claim 16, wherein the composition is selected from the group consisting of Lactobacilli and Bifidobacteria.
18. A method according to claim 16, wherein the lactic acid bacterium is selected from the group consisting of Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei or Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, and mixtures thereof.
19. A method according to claim 16, wherein the lactic acid bacterium is selected from the group consisting of CNCM I-1225, CNCM I-2116, CNCM I-2168 and CNCM I-2170.
20. A method according to claim 16, wherein the probiotic lactic acid bacterium is included into the carrier in a form selected from the group consisting of live form, semi-active and deactivated form.
21. A method according to claim 16, wherein the carotenoid is selected from the group consisting of a cartenoid with and without provitamin A activity.
22. A method according to claim 16, wherein the carrier is a food.
23. A method according to claim 16, wherein the food is selected from the group consisting of milk, yoghurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk based powders, and infant formula.
24. A method according to claim 16, wherein the food may be in a drinkable solution.
25. A composition according to claim 1, wherein the probiotic lactic acid bacterium is included into the carrier in a lyophilized powder attention.
26. A composition according to claim 1, wherein the carotenoid is selected from the group consisting of β-carotene, γ-carotene, α-carotene, lycopene, zeaxanthine and luteine, or mixtures thereof.
27. A composition according to claim 1, wherein the carrier is a pharmaceutical product.
28. A composition according to claim 7, wherein the pharmaceuticals carrier is selected from the group consisting of tablets, liquid suspensions, dried oral supplement, wet oral supplement, and dry-tube-feeding.
29. A composition according to claim 1, wherein the carrier is a nutritional supplement for oral administration.
30. A composition according to claim 29, wherein the nutritional supplement for oral administration is in a form selected from the group consisting of capsules, soft capsules, tablets, pastes or pastilles, gums, drinkable solutions, and emulsions.
US10/505,305 2002-02-21 2003-02-18 Orally administrable composition for the photoprotection of the skin Abandoned US20050069505A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/772,704 US10688139B2 (en) 2002-02-21 2007-07-02 Orally administrable composition for the photoprotection of the skin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02075703.5 2002-02-21
EP02075703 2002-02-21
PCT/EP2003/001685 WO2003070203A1 (en) 2002-02-21 2003-02-18 Orally administrable composition for the photoprotection of the skin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/772,704 Division US10688139B2 (en) 2002-02-21 2007-07-02 Orally administrable composition for the photoprotection of the skin

Publications (1)

Publication Number Publication Date
US20050069505A1 true US20050069505A1 (en) 2005-03-31

Family

ID=27741186

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/505,305 Abandoned US20050069505A1 (en) 2002-02-21 2003-02-18 Orally administrable composition for the photoprotection of the skin
US11/772,704 Active 2027-09-10 US10688139B2 (en) 2002-02-21 2007-07-02 Orally administrable composition for the photoprotection of the skin

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/772,704 Active 2027-09-10 US10688139B2 (en) 2002-02-21 2007-07-02 Orally administrable composition for the photoprotection of the skin

Country Status (23)

Country Link
US (2) US20050069505A1 (en)
EP (1) EP1478329B1 (en)
JP (1) JP2005526038A (en)
KR (1) KR20040096604A (en)
CN (1) CN1301708C (en)
AR (1) AR038594A1 (en)
AT (1) ATE325604T1 (en)
AU (1) AU2003232184B2 (en)
BR (1) BR0307875B1 (en)
CA (1) CA2477144C (en)
DE (1) DE60305159T2 (en)
DK (1) DK1478329T3 (en)
ES (1) ES2263990T3 (en)
HK (1) HK1079104A1 (en)
MX (1) MXPA04008177A (en)
NO (1) NO20043848L (en)
PL (1) PL372146A1 (en)
PT (1) PT1478329E (en)
RU (1) RU2309760C2 (en)
TW (1) TWI344845B (en)
UA (1) UA77066C2 (en)
WO (1) WO2003070203A1 (en)
ZA (1) ZA200407551B (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050238631A1 (en) * 2003-12-04 2005-10-27 Steve Burwell Methods and compositions for preventing biofilm formation, reducing existing biofilms, and for reducing populations of bacteria
US20070042005A1 (en) * 2003-03-26 2007-02-22 Michael Crothers Pharmaceutical composition comprising fungal cell or fragment thereof
US20070280999A1 (en) * 2002-02-21 2007-12-06 Nestec S.A. Orally administrable composition for the photoprotection of the skin
US20090118227A1 (en) * 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
US20090118228A1 (en) * 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
US20090118229A1 (en) * 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
US20110082218A1 (en) * 2006-06-15 2011-04-07 Karin Wertz Treatment and modulation of gene expression and skin aging
US20120064051A1 (en) * 2009-05-11 2012-03-15 Nestec S.A. Infant and young children feeding formula comprising probiotics for infants and young children
US20130004540A1 (en) * 2010-11-11 2013-01-03 O'mahony Liam Bifidobacterium strain
US20130316041A1 (en) * 2011-08-19 2013-11-28 Steven J. Maranz Use of probiotic organisms synthesizing carotenoid compounds to enhance human health and nutrition
US9439933B2 (en) * 2010-06-28 2016-09-13 Kabushiki Kaisha Yakult Honsha Skin properties improving agent for oral administration
WO2023079276A1 (en) * 2021-11-03 2023-05-11 Iiaa Limited Compositions comprising probiotic and postbiotic strains of bacteria

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2297181T3 (en) * 2002-02-21 2008-05-01 Societe Des Produits Nestle S.A. A PHOTOPROTECTOR COMPOSITION FOR THE SKIN, ORAL ADMINISTRATION.
US8088363B2 (en) 2002-10-28 2012-01-03 Zeavision Llc Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
WO2006037922A1 (en) * 2004-10-04 2006-04-13 L'oreal Cosmetic and/or dermatological composition for sensitive skins
FR2876029B1 (en) * 2004-10-04 2008-11-14 Oreal COSMETIC AND / OR DERMATOLOGICAL COMPOSITION FOR SENSITIVE SKINS.
US20060269508A1 (en) 2005-03-29 2006-11-30 Trejo Amy V Means for regulating the cosmetic appearance and/or health of human keratinous tissue
EP2308566B1 (en) * 2005-04-08 2017-07-05 The Procter and Gamble Company Use of orally administered probiotic bifidobacteria for human beauty benefits
AT501919B1 (en) * 2005-06-14 2008-09-15 Erber Ag PROBIOTIC, HEALTH OR BZW. PERFORMANCE-ADDING FEED AND / OR DRINKING WATER SUPPLEMENT FOR ANIMALS AND ITS USE
FR2920305B1 (en) 2007-09-04 2010-07-30 Oreal USE OF A SPECIFIC BIFIDOBACTERIUM LYSATE FOR THE TREATMENT OF SENSITIVE SKINS.
FR2920304B1 (en) 2007-09-04 2010-06-25 Oreal COSMETIC USE OF LYSAT BIFIDOBACTERIUM SPECIES FOR THE TREATMENT OF DROUGHT.
FR2942719B1 (en) 2009-03-04 2011-08-19 Oreal USE OF PROBIOTIC MICROORGANISMS TO LIMIT SKIN IRRITATION
FR2953408B1 (en) * 2009-12-08 2013-02-08 Oreal ACTIVE PROBIOTIC MICROORGANISMS FOR SKIN DYE SKIN
BR112012016676A2 (en) * 2010-01-06 2018-06-05 Kabushiki Kaisha Yakult Honsa promoter of DNA damage repair for oral application and inhibitor of elastase activity for oral application.
PT2693885T (en) * 2011-04-08 2018-06-04 Chr Hansen As Synergistic antimicrobial effect
MY187589A (en) 2011-06-20 2021-09-30 Heinz Co Brands H J Llc Probiotic compositions and methods
CN108771687A (en) 2012-02-29 2018-11-09 伊西康内外科公司 The composition of microbiota and relative method
ES2630711T3 (en) 2012-04-09 2017-08-23 Chr. Hansen A/S Bioprotection using strains of Lactobacillus rhamnosus
EP2836588B1 (en) 2012-04-09 2017-03-01 Chr. Hansen A/S Bioprotection using lactobacillus paracasei strains
CN113730442A (en) 2014-10-31 2021-12-03 潘德勒姆治疗公司 Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3270938A4 (en) * 2015-03-18 2018-12-19 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders
EP3359174A1 (en) * 2015-10-07 2018-08-15 Galderma Research & Development Composition containing lactic acid bacteria and its use to treat atopic dermatitis
CA3073838A1 (en) 2017-08-30 2019-03-07 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
EP3716958B1 (en) * 2017-11-28 2023-10-18 Dermapharm AG Composition for the treatment of dysbiosis of the intestinal microbiota
DE102018000033A1 (en) * 2018-01-03 2019-07-25 Torsten Schott Process for accelerated general and skin regeneration and wound healing

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US539773A (en) * 1895-05-21 Carburetor
US3920834A (en) * 1970-07-10 1975-11-18 Hoffmann La Roche Light-screening compositions and method
US4464362A (en) * 1980-06-27 1984-08-07 Estee Lauder Inc. Topical skin repair composition
US4646362A (en) * 1985-01-10 1987-03-03 Kimberly-Clark Corporation Disposable underpants, such as child's training pants and the like
US4806368A (en) * 1987-09-16 1989-02-21 Reddy Malireddy S Shelf life and subsequent growth of lactobacillus acidophilus, propionibacterium shermanii and leuconostoc citrovorum in dietary fiber based supplement preparation
US5192565A (en) * 1990-09-28 1993-03-09 Nestec S.A. Preservation of vegetables and fruits
US5501857A (en) * 1992-07-24 1996-03-26 Midwestern Bio-Ag Products & Services, Inc. Oral nutritional and dietary composition
US5603930A (en) * 1992-07-06 1997-02-18 Nestec S.A. Lactobacillus johnsonii CNCM I-1225
US6030650A (en) * 1996-11-22 2000-02-29 Princeton Nutrition, L.L.C. Complete nutritional milk compositions and products
US6110478A (en) * 1996-06-12 2000-08-29 Laboratoire Oenobiol Composition having tanning and photoprotective activity, and its cosmetic applications
US6156355A (en) * 1998-11-02 2000-12-05 Star-Kist Foods, Inc. Breed-specific canine food formulations
US6254886B1 (en) * 1997-12-19 2001-07-03 Merck Patent Gmbh Multilayer tablet
US20010006671A1 (en) * 2000-01-03 2001-07-05 Louis P. Goodman Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements
US20030059501A1 (en) * 2000-05-03 2003-03-27 Vincent Rivier Confectionery product containing functional ingredients
US20040013732A1 (en) * 2001-09-25 2004-01-22 Michael Farber Starch-based delivery system for creatine
US20050158291A1 (en) * 2002-02-21 2005-07-21 Lionel Breton Pet food composition for skin photoprotection
US7037708B1 (en) * 1998-04-30 2006-05-02 Basf Aktiengesellschaft Dried microorganism cultures and method for producing same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223491A (en) 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
FR2698268B1 (en) 1992-11-24 1995-01-20 Oreal Photoprotective composition administered orally.
JP3347381B2 (en) * 1993-01-27 2002-11-20 協和醗酵工業株式会社 Pet food
FR2718752B1 (en) 1994-04-15 1996-07-12 World Trust Investment Sa Preparations based on fermented whey and their uses.
FR2725896B1 (en) 1994-10-19 1996-11-29 Sederma Sa NEW COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS
IT1274654B (en) 1995-02-28 1997-07-18 Newpharma Srl ASSOCIATIONS OF LACTIC FERMENTS AND SACCHAROMETIC LYSATES THEIR THERAPEUTIC USE AND COMPOSITIONS CONTAINING THEM
CA2326874C (en) * 1998-04-01 2010-05-25 Ganeden Biotech, Inc. Methods for reducing cholesterol using bacillus coagulans spores, systems and compositions
NL1010770C2 (en) 1998-12-09 2000-06-13 Nutricia Nv Preparation containing oligosaccharides and probiotics.
EP1020123A1 (en) * 1999-01-18 2000-07-19 Sitia-Yomo S.p.A. Beverages containing live lactic bacteria
SE523771C2 (en) * 1999-05-21 2004-05-18 Probi Ab Sports drinks containing micronutrients in combination with live lactobacilli
JP2001000142A (en) * 1999-06-23 2001-01-09 Artnature Co Ltd Nutritive assistance food for hair restoration and hair growth
PE20010524A1 (en) * 1999-09-09 2001-05-23 Nestle Sa NUTRITIONAL COMPOSITION FOR DOMESTIC ANIMALS CONTAINING A SOURCE OF NUTRIENTS WITH ANTIOXIDANT PROPERTIES
EP1110555A1 (en) * 1999-12-22 2001-06-27 Societe Des Produits Nestle S.A. Antiadhesive agent for the pathogen flora of the skin
DE60125345T2 (en) * 2000-03-24 2007-09-27 Société des Produits Nestlé S.A. MILKY ACID BACTERIUM FOR THE PREVENTION OF BELLY FENCE IGNITION
PT1322318E (en) * 2000-10-06 2011-03-15 Oreal Use of probiotic lactic acid bacteria for preventing ultraviolet radiation induced inflammatory or allergic reaction or immunosuppression in the skin
US6864231B2 (en) 2001-01-09 2005-03-08 Pharmachem Laboratories, Inc. Glycoprotein matrix compositions and methods related thereto
UA77066C2 (en) * 2002-02-21 2006-10-16 Nestle Sa Orally administrable composition for the photoprotection of the skin
ES2297181T3 (en) * 2002-02-21 2008-05-01 Societe Des Produits Nestle S.A. A PHOTOPROTECTOR COMPOSITION FOR THE SKIN, ORAL ADMINISTRATION.

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US539773A (en) * 1895-05-21 Carburetor
US3920834A (en) * 1970-07-10 1975-11-18 Hoffmann La Roche Light-screening compositions and method
US4464362A (en) * 1980-06-27 1984-08-07 Estee Lauder Inc. Topical skin repair composition
US4646362A (en) * 1985-01-10 1987-03-03 Kimberly-Clark Corporation Disposable underpants, such as child's training pants and the like
US4806368A (en) * 1987-09-16 1989-02-21 Reddy Malireddy S Shelf life and subsequent growth of lactobacillus acidophilus, propionibacterium shermanii and leuconostoc citrovorum in dietary fiber based supplement preparation
US5192565A (en) * 1990-09-28 1993-03-09 Nestec S.A. Preservation of vegetables and fruits
US5603930A (en) * 1992-07-06 1997-02-18 Nestec S.A. Lactobacillus johnsonii CNCM I-1225
US5501857A (en) * 1992-07-24 1996-03-26 Midwestern Bio-Ag Products & Services, Inc. Oral nutritional and dietary composition
US6110478A (en) * 1996-06-12 2000-08-29 Laboratoire Oenobiol Composition having tanning and photoprotective activity, and its cosmetic applications
US6030650A (en) * 1996-11-22 2000-02-29 Princeton Nutrition, L.L.C. Complete nutritional milk compositions and products
US6254886B1 (en) * 1997-12-19 2001-07-03 Merck Patent Gmbh Multilayer tablet
US7037708B1 (en) * 1998-04-30 2006-05-02 Basf Aktiengesellschaft Dried microorganism cultures and method for producing same
US6156355A (en) * 1998-11-02 2000-12-05 Star-Kist Foods, Inc. Breed-specific canine food formulations
US20010006671A1 (en) * 2000-01-03 2001-07-05 Louis P. Goodman Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements
US20030059501A1 (en) * 2000-05-03 2003-03-27 Vincent Rivier Confectionery product containing functional ingredients
US20040013732A1 (en) * 2001-09-25 2004-01-22 Michael Farber Starch-based delivery system for creatine
US20050158291A1 (en) * 2002-02-21 2005-07-21 Lionel Breton Pet food composition for skin photoprotection

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070280999A1 (en) * 2002-02-21 2007-12-06 Nestec S.A. Orally administrable composition for the photoprotection of the skin
US20070042005A1 (en) * 2003-03-26 2007-02-22 Michael Crothers Pharmaceutical composition comprising fungal cell or fragment thereof
US20050238631A1 (en) * 2003-12-04 2005-10-27 Steve Burwell Methods and compositions for preventing biofilm formation, reducing existing biofilms, and for reducing populations of bacteria
US20110082218A1 (en) * 2006-06-15 2011-04-07 Karin Wertz Treatment and modulation of gene expression and skin aging
US20090118227A1 (en) * 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
US20090118229A1 (en) * 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
US20090118228A1 (en) * 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
US9072314B2 (en) 2007-11-07 2015-07-07 Mead Johnson Nutrition Company Carotenoid-containing compositions and methods
US20120064051A1 (en) * 2009-05-11 2012-03-15 Nestec S.A. Infant and young children feeding formula comprising probiotics for infants and young children
US9439933B2 (en) * 2010-06-28 2016-09-13 Kabushiki Kaisha Yakult Honsha Skin properties improving agent for oral administration
US20130004540A1 (en) * 2010-11-11 2013-01-03 O'mahony Liam Bifidobacterium strain
US9259019B2 (en) * 2010-11-11 2016-02-16 Mars, Incorporated Bifidobacteriumstrain
US20130316041A1 (en) * 2011-08-19 2013-11-28 Steven J. Maranz Use of probiotic organisms synthesizing carotenoid compounds to enhance human health and nutrition
US9113653B2 (en) * 2011-08-19 2015-08-25 Steven J Maranz Methods of administering probiotic organisms that synthesize carotenoid compounds in situ to enhance human health and nutrition
WO2023079276A1 (en) * 2021-11-03 2023-05-11 Iiaa Limited Compositions comprising probiotic and postbiotic strains of bacteria

Also Published As

Publication number Publication date
PT1478329E (en) 2006-09-29
MXPA04008177A (en) 2005-06-08
NO20043848L (en) 2004-09-14
ES2263990T3 (en) 2006-12-16
AU2003232184B2 (en) 2008-11-13
TW200307555A (en) 2003-12-16
EP1478329B1 (en) 2006-05-10
CA2477144C (en) 2011-06-14
DK1478329T3 (en) 2006-08-28
TWI344845B (en) 2011-07-11
JP2005526038A (en) 2005-09-02
RU2004127986A (en) 2005-05-10
DE60305159D1 (en) 2006-06-14
DE60305159T2 (en) 2007-03-15
PL372146A1 (en) 2005-07-11
HK1079104A1 (en) 2006-03-31
BR0307875B1 (en) 2014-12-23
ATE325604T1 (en) 2006-06-15
WO2003070203A1 (en) 2003-08-28
US20070280999A1 (en) 2007-12-06
AU2003232184A1 (en) 2003-09-09
AR038594A1 (en) 2005-01-19
ZA200407551B (en) 2005-10-12
CN1635865A (en) 2005-07-06
CN1301708C (en) 2007-02-28
EP1478329A1 (en) 2004-11-24
US10688139B2 (en) 2020-06-23
CA2477144A1 (en) 2003-08-28
UA77066C2 (en) 2006-10-16
KR20040096604A (en) 2004-11-16
RU2309760C2 (en) 2007-11-10
BR0307875A (en) 2004-12-28

Similar Documents

Publication Publication Date Title
US10688139B2 (en) Orally administrable composition for the photoprotection of the skin
EP1490077B1 (en) A photoprotective orally administrable composition for skin
CA2424607C (en) Use of probiotic lactic acid bacteria for balancing the skin's immune system
AU2003210311C1 (en) Pet food composition for skin photoprotection
AU2003210310B2 (en) A photoprotective orally administrable composition for skin

Legal Events

Date Code Title Description
AS Assignment

Owner name: NESTEC S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRETON, LIONEL;BUREAU-FRANZ, ISABELLE;FANCHON, CHANTAL;REEL/FRAME:015297/0096

Effective date: 20040823

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION